Timothy Block

US Patent:

8097728, Jan 17, 2012

Filed:

Apr 30, 2008

Appl. No.:

12/112694

Inventors:

Baohua Gu - Malvern PA, US
Timothy M. Block - Doylestown PA, US
Robert M. Moriarty - Michigan City IN, US
Mahendra N. Deshpande - Gurnee IL, US
Rajendra C. Shah - Morton Grove IL, US

Assignee:

Philadelphia Health & Education Corporation - Philadelphia PA
The Board Of Trustees Of The University of Illinois - Urbana IL

International Classification:

C12N 9/99
A61P 31/14
C07D 211/40

US Classification:

546219, 435184

Abstract:

An anti-viral compounds effective against viruses belonging to the Flaviviridae family, wherein the anti-viral compounds are 1,5-dideoxy-1,5-imino-D-glucitol derivative compounds having the general formula (I).

US Patent:

8193328, Jun 5, 2012

Filed:

Sep 7, 2006

Appl. No.:

12/065840

Inventors:

Xuanyong Lu - Horsham PA, US
Timothy Block - Doylestown PA, US

Assignee:

Philadelphia Health & Education Corporation - Philadelphia PA

International Classification:

C12N 15/15
C12N 15/11
C12N 15/113

US Classification:

536 235, 536 234, 536 245

Abstract:

This invention describes a relevant etiology of cancer and a novel anti-cancer therapeutic strategy, based on the discovery that a protein named serine protease inhibitor (SPIK/SPINK/PSTI) was up-regulated by hepatitis B and C virus infections consequently suppressing the cell apoptosis. Accordingly, this invention provides an inhibitor of SPIK and/or a technology of suppression of over-expression of SPIK in cells. The inhibitors include: 1) chemical compounds, which can inhibit SPIK transcripts, protein activity, and gene expression, 2) SPIK siRNA (RNAi gene silence or dsRNA of SPIK, 3) DNA anti-sense and anti-SPIK antibody. Further, this invention provides a method of using the inhibitor as an anti-cancer agent to re-instate cancer cell apoptosis (e. g. , serine protease dependent cell apoptosis).

US Patent:

8568984, Oct 29, 2013

Filed:

Feb 18, 2011

Appl. No.:

13/030888

Inventors:

Ying-Hsiu Su - Audubon PA, US
Benjamin Song - Audubon PA, US
Janet Song - Audubon PA, US
Timothy M. Block - Doylestown PA, US

Assignee:

Philadelphia Health & Education Corporation - Philadelphia PA

International Classification:

C07H 21/04
C12Q 1/68

US Classification:

435 612, 435 611, 435 691, 536 231, 536 243

Abstract:

Provided are methods of diagnosing and/or determining treatment of non-urinary tract cancers by detecting biomarkers, and aberrant methylation in said biomarkers, in human urine samples.

US Patent:

8609668, Dec 17, 2013

Filed:

May 4, 2007

Appl. No.:

12/299532

Inventors:

Andrea Cuconati - Oreland PA, US
Timothy M. Block - Doylestown PA, US
Xiaodong Xu - Doylestown PA, US

Assignee:

Philadelphia Health & Education Corporation - Philadelphia PA
Institute For Hepatitis and Virus Research - Doylestown PA

International Classification:

A61K 31/519
A61P 31/20
C07D 487/04

US Classification:

5142593, 544254

Abstract:

A pharmaceutical composition comprising an effective amount of a compound of formulas (I-III) and a pharmaceutically acceptable carrier. Methods for treating a hepatitis virus in a patient comprising administering an effective amount of the compound of formulas (I-III) are also presented.

US Patent:

20100285469, Nov 11, 2010

Filed:

Oct 10, 2008

Appl. No.:

12/680654

Inventors:

Ying-Hsiu Su - Audubon PA, US
Zhili Wang - Bryn Mawr PA, US
Timothy M. Block - Doylestown PA, US
Janet Song - Audubon PA, US

Assignee:

Philadelphia Health & Education d/b/a Drexel University College of Medicine - Philadelphia PA
The Children's Hospital Of Philadelphia - Philadelphia PA

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

A method for tumor screening using urine of a mammal, the method includes obtaining a total urine nucleic acid (e.g., DNA) from a urine sample of a mammal, extracting a high molecular weight urine nucleic acid (above 1000 bp) by contacting the total urine nucleic acid with an adsorbent in the presence of a buffer which promotes binding of the high molecular weight urine nucleic acid to the adsorbent, replacing the buffer which promotes binding of the high molecular weight urine nucleic acid with a buffer which promotes binding of the low molecular weight urine nucleic acid to the adsorbent, extracting the low molecular weight urine nucleic acid by contacting with the adsorbent, eluting the low molecular weight urine nucleic acid, and assaying the low molecular weight urine nucleic acid for a presence or absence of a gene sequence specific to a certain type of tumor.

US Patent:

20110053141, Mar 3, 2011

Filed:

Aug 24, 2010

Appl. No.:

12/862545

Inventors:

Xiangdong Ren - Malvern PA, US
Timothy Block - Doylestown PA, US
Hui Nie - Doyletown PA, US

Assignee:

INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH - Doylestown PA

International Classification:

C12Q 1/70

US Classification:

435 5

Abstract:

This invention provides compositions and methods for ultrasensitive detection and quantification of mutant hepatitis B viruses (HBV). The compositions and methods of the invention can be used to detect HBV mutations for diagnostic and prognostic purposes. This invention also provides new application of a TaqMan hydrolysis probe in asymmetric real time PCR and melting curve analysis.

US Patent:

20120244160, Sep 27, 2012

Filed:

May 25, 2012

Appl. No.:

13/480886

Inventors:

Xuanyong Lu - Horsham PA, US
Timothy Block - Doylestown PA, US

Assignee:

PHILADELPHIA HEALTH & EDUCATION CORPORATION, D/B/A Drexel University College of Medicine - Philadelphia PA

International Classification:

A61K 31/713
C12Q 1/02
C07H 21/02
C07K 16/40
A61K 39/395
C40B 30/08
C12Q 1/68

US Classification:

4241351, 506 11, 435 29, 435 613, 5303873, 536 245, 5303879, 514 44 A

Abstract:

This disclosure describes a relevant etiology of cancer and a novel anti-cancer therapeutic strategy, based on the discovery that a protein named serine protease inhibitor (SPIK/SPINK/PSTI) was up-regulated by hepatitis B and C virus infections consequently suppressing the cell apoptosis. Accordingly, the present disclosure provides, inter alia, an inhibitor of SPIK and/or a technology of suppression of over-expression of SPIK in cells. The inhibitors include: 1) chemical compounds, which can inhibit SPIK transcripts, protein activity, and gene expression, 2) SPIK siRNA (RNAi gene silence or dsRNA of SPIK, 3) DNA anti-sense and anti-SPIK antibody. Further, this disclosure provides methods of using the inhibitor as an anti-cancer agent to re-instate cancer cell apoptosis (e.g., serine protease dependent cell apoptosis).

US Patent:

20130280255, Oct 24, 2013

Filed:

Jul 8, 2013

Appl. No.:

13/937153

Inventors:

Xuanyong Lu - Horsham PA, US
Timothy M. Block - Doylestown PA, US

International Classification:

C12Q 1/37

US Classification:

4241351, 435 23, 530350, 536 231, 5303879, 514 43, 514 193, 4241581, 514 44 A, 536 245, 506 11, 435 613

Abstract:

This disclosure describes a relevant etiology of cancer and a novel anti-cancer therapeutic strategy, based on the discovery that a protein named serine protease inhibitor (SPIK/SPINK/PSTI) was up-regulated by hepatitis B and C virus infections consequently suppressing the cell apoptosis. Accordingly, the present disclosure provides, inter alia, an inhibitor of SPIK and/or a technology of suppression of over-expression of SPIK in cells. The inhibitors include: 1) chemical compounds, which can inhibit SPIK transcripts, protein activity, and gene expression, 2) SPIK siRNA (RNAi gene silence or dsRNA of SPIK, 3) DNA anti-sense and anti-SPIK antibody. Further, this disclosure provides methods of using the inhibitor as an anti-cancer agent to re-instate cancer cell apoptosis (e.g., serine protease dependent cell apoptosis).

Author:

Timothy A. Block

ISBN #:

0812235355

Author:

Timothy A. Block

ISBN #:

0812237854

Author:

Timothy A. Block

ISBN #:

0812240030